KYTX Kyverna Therapeutics, Inc.
Kyverna Therapeutics, Inc. (KYTX) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
How much of that selling was preplanned? 100% planned / 0% discretionary
Largest single sale: $292.8K.
Where they traded
Last open-market purchase: December 18, 2025 .
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| Buy | 133,333 | $7.50 | $1000.0K | 869,317 | |||
| SEIDENBERG BETH C | Director | Buy | 133,333 | $7.50 | $1000.0K | 869,317 | |
| Walker Karen Marie | Chief Technology Officer | Sell 10b5-1 | 23,998 | $12.20 | $292.8K | 22,636 −51.5% of holding |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.